Active substanceCalcium gluconateCalcium gluconate
Similar drugsTo uncover
  • Calcium gluconate
    pills inwards 
    ATOLL, LLC     Russia
  • Calcium gluconate
    solution w / m in / in 
    ELLARA, LTD.     Russia
  • Calcium gluconate
    solution w / m in / in 
  • Calcium gluconate
    pills inwards 
  • Calcium gluconate
    solution w / m in / in 
    ATOLL, LLC     Russia
  • Calcium gluconate
    pills inwards 
  • Calcium gluconate
    pills inwards 
    URALBIOFARM, OJSC     Russia
  • Calcium gluconate
    pills inwards 
    BIOSINTEZ, PAO     Russia
  • Calcium gluconate
    solution w / m in / in 
    BINNOFARM, CJSC     Russia
  • Calcium gluconate
    solution w / m in / in 
    TRIM, LLC     Russia
  • Calcium gluconate
    pills inwards 
    LYUMI, LLC     Russia
  • Calcium gluconate
    pills inwards 
    UPDATE OF PFC, CJSC     Russia
  • Calcium gluconate
    solution w / m in / in 
    DALHIMFARM, OJSC     Russia
  • Calcium gluconate
    pills inwards 
    MEDISORB, CJSC     Russia
  • Calcium gluconate
    solution w / m in / in 
  • Calcium gluconate
    solution w / m in / in 
    ESKOM NPK, OAO     Russia
  • Calcium gluconate
    pills inwards 
    AVEKSIMA, JSC     Russia
  • Calcium gluconate
    solution w / m in / in 
  • Calcium gluconate
    solution w / m in / in 
    BIOSINTEZ, PAO     Russia
  • Calcium gluconate, stabilized
    solution for injections 
    FARMAK, PAO     Ukraine
  • Calcium gluconate, stabilized
    solution w / m in / in 
  • Calcium gluconate Extrabate
    pills inwards 
  • Calcium gluconate-Vial
    solution w / m in / in 
    VIAL, LLC     Russia
  • Calcium gluconate-lekT
    pills inwards 
  • Calcium gluconate-SOLOfarm
    solution w / m in / in 
    GROTEKS, LLC     Russia
  • Dosage form: & nbsppills
    Composition:

    Composition per one tablet

    Active substance: calcium gluconate monohydrate - 500 mg;

    Excipients: potato starch - 13.3 mg, talc - 12.5 mg, calcium stearate - 4.2 mg.

    Description:Tablets of white color are flat-cylindrical, with a facet and a risk. Marble is allowed on the surface of the tablets.
    Pharmacotherapeutic group:Calcium-phosphorus exchange regulator
    ATX: & nbsp

    A.12.A.A.03   Calcium gluconate

    A.12.A.A   Calcium preparations

    Pharmacodynamics:Calcium ions are involved in the formation of bone tissue, the process of blood coagulation, are necessary to maintain stable cardiac activity, to carry out the processes of transmission of nerve impulses.The decrease in the content of calcium ions in the blood plasma and tissues can lead to the development of various pathological processes. Hypocalcemia leads to disruption of the function of skeletal and smooth muscles, cardiovascular system, impaired blood coagulation, and the development of osteoporosis.
    Pharmacokinetics:

    Approximately 1 / 5-1 / 3 part of the orally administered drug is absorbed into the small intestine. This process depends on the influence of the vitamin D, the acidity of the intestinal contents, the characteristics of the diet and the presence of factors capable of binding calcium ions. The absorption of calcium increases with its deficiency in the body and in food. About 20% of calcium is excreted by the kidneys, the remaining 80% is removed from the intestinal contents (calcium is actively excreted through the wall of the terminal intestine).

    Indications:

    Hypoparathyroidism (latent tetany, osteoporosis), metabolic disorders of vitamin D: rickets (spasmophilia, osteomalacia), hyperphosphatemia in patients with chronic renal failure.

    The increased need for calcium (pregnancy, the period of breastfeeding, the period of increased growth of the body), insufficient calcium in the diet, a violation of its metabolism (in the postmenopausal period).

    Enhanced excretion of calcium (prolonged bed rest, chronic diarrhea, secondary hypocalcemia, long-term use of diuretics, antiepileptic drugs and glucocorticosteroids).

    Poisoning with magnesium salts, oxalic and fluoric acids and their soluble salts (in the interaction with calcium gluconate insoluble and non-toxic calcium oxalate and calcium fluoride are formed).

    Hyperkaliemic form of paroxysmal myoplegia.

    Contraindications:

    Hypersensitivity, hypercalcemia (concentration of calcium ions should not exceed 12 mg% = 6 mEq / L), expressed hypercalciuria, nephrourolythiasis (calcium), sarcoidosis, severe renal failure, simultaneous reception of cardiac glycosides (risk of arrhythmias), children under 3 years.

    Carefully:

    Dehydration, diarrhea, malabsorption syndrome, mild chronic renal and / or cardiovascular insufficiency, hypercoagulation. Patients with a small hypercalciuria, with minor impairment of kidney function or with a history of urolithiasis, should be administered with caution and regularly monitor the level of calcium excretion in the urine.

    If you have one of these diseases, consult a doctor before taking the drug.

    Pregnancy and lactation:

    During pregnancy and during breastfeeding, the use of the drug is possible on the recommendation of a doctor. The daily dose of calcium during pregnancy should not exceed 1500 mg.

    Dosing and Administration:

    The drug is taken orally before meals or 1.5-2 hours after eating, washed down with milk.

    The dosage regimen and the duration of administration of the drug for each indication depend on the patient's condition and are determined by the physician in accordance with the following therapy regimens.

    Adults and children over 14 years of age - 1.0-3.0 g (2-6 tablets) 2-3 times a day; children from 3 to 5 years - 1.0 g (2 tablets) 2-3 times a day; from 5 to 7 years - 1.0-1.5 g (2-3 tablets) 2-3 times a day; from 7 to 10 years - 1,5-2,0 g (3-4 tablets) 2-3 times a day; from 10 to 14 years - 2.0-3.0 g (4-6 tablets) 2-3 times a day.

    Side effects:

    Constipation, irritation of the mucous membrane of the gastrointestinal tract, hypercalcemia, allergic reactions. If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.

    Overdose:

    Symptoms: elevated serum calcium levels.With chronic overdose with calcium preparations, general and muscle weakness, depression, mental disorders, eating disorders, nausea, vomiting, constipation, lowering of blood pressure, disturbance of the heart rhythm can develop.

    Treatment: withdrawal of the drug, parenteral administration of calcitonin in a dose of 5-10 IU / kg / day in 500 ml of 0.9% sodium chloride solution for 6 hours.

    Interaction:

    Calcium gluconate is pharmaceutically incompatible with carbonates, salicylates, sulfates, as it precipitates them to form insoluble and sparingly soluble calcium salts.

    Simultaneous reception of calcium gluconate with thiazide diuretics leads to increased hypercalcemia.

    The intake of calcium gluconate reduces the effect of calcitonin in hypercalcemia, and also reduces the bioavailability of phenytoin.

    Due to the formation of insoluble complexes, it is incompatible with licorice root preparations and tetracycline antibiotics (reduces the antibacterial effect). Slows the absorption of digoxin, tetracyclines, iron preparations for oral administration (the interval between taking calcium gluconate and listed drugs should be at least 2 hours).

    With the simultaneous use of calcium gluconate with quinidine, an inhibition of intraventricular conduction and an increase in quinidine toxicity are possible.

    Special instructions:

    Patients with a tendency to kidney stones are encouraged to increase the amount of fluid consumed.

    Effect on the ability to drive transp. cf. and fur:

    The drug does not affect the ability to drive a car or to control various mechanisms, as well as to engage in other potentially dangerous activities that require increased attention and speed of mental and motor reactions.

    Form release / dosage:Tablets of 500 mg.
    Packaging:

    For 10 tablets in a planar cell packaging made of polyvinylchloride film and aluminum foil printed lacquered or in contour non-cellular packaging made of packaging material from combined materials.

    2, 3, 5 or 10 contour packs together with instructions for use are placed in a pack of cardboard.

    Contourcell or cell-free packages with an equal number of instructions are placed in a group package.

    Storage conditions:

    At a temperature of no higher than 25 ° C. Keep out of the reach of children.

    Shelf life:

    5 years.Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LS-002163
    Date of registration:23.07.2010 / 18.02.2013
    Expiration Date:Unlimited
    The owner of the registration certificate:PHARMSTANDART-FORESTRY, OJSC PHARMSTANDART-FORESTRY, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp24.11.2017
    Illustrated instructions
      Instructions
      Up